Cargando…

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases

PURPOSE: (153)Sm-ethylenediaminetetramethylenephosphonic acid (EDTMP; Quadramet®) is indicated for the treatment of painful bone metastases, whereas zoledronic acid (Zometa®) is indicated for the prevention of skeletal complications. Because of the different therapeutic effects, combining the treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lam, Marnix G. E. H., Dahmane, Amel, Stevens, Wil H. M., van Rijk, Peter P., de Klerk, John M. H., Zonnenberg, Bernard A.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2007
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668561/ https://www.ncbi.nlm.nih.gov/pubmed/18157530 http://dx.doi.org/10.1007/s00259-007-0659-z

Ejemplares similares

Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis
por: Ayati, Narjess, et al.
Publicado: (2013)

Comparison of Tc-99m MDP and Sm-153 EDTMP bone scan
por: Ramachandran, Krishnakumar, et al.
Publicado: (2011)

Treatment of severe hypocalcaemia due to osteoblastic metastases in a patient with post-thyroidectomy hypoparathyroidism with (153)Sm-EDTMP
por: Kassi, Eva, et al.
Publicado: (2017)

Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2008)

Comparative Therapeutic Efficacy of (153)Sm-EDTMP and (177)Lu-EDTMP for Bone Pain Palliation in Patients with Skeletal Metastases: Patients’ Pain Score Analysis and Personalized Dosimetry
por: Sharma, Sarika, et al.
Publicado: (2017)

Toxicity of Therapy with Sm-153-EDTMP: To What Extend can it be Related to the Tumor Type?
por: Świętaszczyk, Cyprian, et al.
Publicado: (2016)

(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study
por: Lam, Marnix G. E. H., et al.
Publicado: (2009)

Radionuclide Treatment with 153Sm-EDTMP is Effective for the Palliation of Bone Pain in the Context of Extensive Bone Marrow Metastases: A Case Report
por: Kairemo, Kalevi, et al.
Publicado: (2014)

Effects of low-dose capecitabine on Samarium-153-EDTMP therapy for painful bone metastases
por: Barai, Sukanta, et al.
Publicado: (2015)

Beyond Palliation: Therapeutic Applications of (153)Samarium-EDTMP
por: Wilky, Breelyn A., et al.
Publicado: (2013)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

The Level of Europium-154 Contaminating Samarium-153-EDTMP Activates the Radiation Alarm System at the US Homeland Security Checkpoints
por: Najeeb Al Hallak, Mohammed, et al.
Publicado: (2009)

Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
por: Heery, Christopher R., et al.
Publicado: (2016)

Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)
por: Joob, Beuy, et al.
Publicado: (2014)

Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [$^{153}$Sm]Sm-DOTA-TATE
por: Vermeulen, Koen, et al.
Publicado: (2022)

Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [(153)Sm]Sm-DOTA-TATE
por: Vermeulen, Koen, et al.
Publicado: (2022)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical
por: Mercanoglu, Guldem, et al.
Publicado: (2023)

The influence of Sm-153 therapy on bone marrow function
por: Małkowski, Bogdan, et al.
Publicado: (2016)

Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience
por: Rasulova, Nigora, et al.
Publicado: (2013)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

sup 8 sup 9 Sr and sup 1 sup 5 sup 3 Sm-EDTMP therapy of disseminated skeletal metastasis
por: Zhang Jun Ning, et al.
Publicado: (2001)

Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
por: Wendt, Richard E., et al.
Publicado: (2022)

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy
por: Van de Voorde, Michiel, et al.
Publicado: (2021)

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy
por: Van de Voorde, Michiel, et al.
Publicado: (2021)

Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
por: Keeling, A. A., et al.
Publicado: (1989)

Systemic Radiopharmaceutical Agents (Sm-153) may be Dangerous in Hepatacellular Carcinoma
por: Keskin, Onur, et al.
Publicado: (2015)

Production, Quality Control and Pharmacokinetic Studies of (166)Ho-EDTMP for Therapeutic Applications
por: Bahrami-Samani, Ali, et al.
Publicado: (2010)

A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer
por: Hong, Sung Joon, et al.
Publicado: (2007)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Development of (153)Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI
por: Gholami, Amir, et al.
Publicado: (2016)

The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and $^{225}$Ac in tumor bearing mice
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1996)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Preparation and Quality Control of the [(153)Sm]-Samarium Maltolate Complex as a Lanthanide Mobilization Product in Rats
por: Naseri, Zohreh, et al.
Publicado: (2011)

RADIOACTIVE CEMENT OF PMMA AND HAP-Sm-153, Ho-166, OR RE-188 FOR BONE METASTASIS TREATMENT
por: Montaño, Carlos Julio, et al.
Publicado: (2019)

Scutellarin Loaded on Ultradeformable Nanoliposome Scutellarin EDTMP (S-UNL-E) Promotes Osteogenesis in Osteoporotic Rats
por: Teng, Minhua, et al.
Publicado: (2022)

The Organon, Section 153
por: Fitz, W. H. A.
Publicado: (1888)

Simultaner Vergleich der Bioverteilung von $^{87}$Y-Citrat and $^{88}$Y-EDTMP tumortragenden Ratten
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1991)

Improved Formulation of (224)Ra-Labeled Calcium Carbonate Microparticles by Surface Layer Encapsulation and Addition of EDTMP
por: Li, Ruth Gong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hdq65ul4duvedgahtcbqi5ru4n